Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05047185 · ClinicalTrials.gov registry record · Phase 2
Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II
A Phase 2 study, sponsored by Pharvaris Netherlands B.V..
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT05047185 is a Phase 2 study that has completed, run by Pharvaris Netherlands B.V.. The registered enrollment target is 34 participants.
The verdict
NCT05047185, a Phase 2 study, has completed, sponsored by Pharvaris Netherlands B.V..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
This study evaluates the safety and efficacy of PHA-022121 administered orally for prophylaxis against angioedema attacks in patients with hereditary angioedema (HAE). The study consists of 2 parts, with patients completing participation in Part 1 prior to initiation of treatment in Part 2. Part 1 of the study has 3 parallel arms and approximately 30 patients will be equally randomized to one of two dose regimens of PHA-022121 or matching placebo. Patients will continue to the single open-label arm in Part 2 of the study after completion of Part 1. The screening period is up to 8 weeks and the treatment periods are 12 weeks (Part 1) and 30 months (Part 2) in duration.
Interventions
- DRUG Placebo
- DRUG Deucrictibant low dose
- DRUG Deucrictibant high dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2022-04-19 |
| Est. Completion | 2025-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05047185
The ClinicalTrials.gov registry entry for NCT05047185 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharvaris Netherlands B.V., which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05047185 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05047185 about?
NCT05047185 is a clinical study titled "Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II". This study evaluates the safety and efficacy of PHA-022121 administered orally for prophylaxis against angioedema attacks in patients with hereditary angioedema (HAE). The study consists of 2 parts, with patients completing participation in Part 1 prior to initiation of treatment in Part 2. Part 1 o...
What is the current status of trial NCT05047185?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2022-04-19. Estimated completion is 2025-06-30.
What interventions are being tested in trial NCT05047185?
The interventions under investigation include: Placebo (DRUG), Deucrictibant low dose (DRUG), Deucrictibant high dose (DRUG).
Who is sponsoring clinical trial NCT05047185?
This trial is sponsored by Pharvaris Netherlands B.V., which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.